Susan Monarez, already acting director of the CDC, said during her confirmation hearing that she sees no causal link between ...

Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic ...

Without providing further context, HHS Secretary Robert F. Kennedy Jr. says that Gavi needs to “start taking vaccine safety ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

Given today’s available local talent pool, biopharma companies are less likely to turn toward international job candidates, ...

Writing in JAMA, four former governmental officials warn that the Trump administration’s involvement in delaying the approval ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

Are long R&D cycles, overwhelming literature reviews, or patent bottlenecks slowing your path to innovation? In the ...

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...

Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said the agency’s new risk-based COVID-19 vaccine framework contradicts the ...

Flagship Pioneering’s ProFound Therapeutics will use its proprietary technology to mine the expanded proteome for novel cardiovascular therapeutics. Novartis has promised to pay up to $750 million per ...

Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move ...